Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04464759 · ClinicalTrials.gov registry record · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
A Phase 1 study of Melanoma, sponsored by Ravi Amaravadi, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT04464759: Recruiting Phase 1 study of Melanoma, sponsored by Ravi Amaravadi, MD.
NCT04464759 is a Phase 1 study of Melanoma that is actively recruiting participants, run by Ravi Amaravadi, MD. The registered enrollment target is 94 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04464759, a Phase 1 study of Melanoma, is actively recruiting participants, sponsored by Ravi Amaravadi, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.
Primary Outcome
To determine the MTD and preliminary safety of HCQ when administered in conjunction with one of the following treatments in patients with advanced melanoma: * HCQ administered in combination with nivolumab; or * HCQ administered in combination with nivolumab and ipilimumab followed by maintenance nivolumab
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Hydroxychloroquine
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2020-10-21 |
| Est. Completion | 2025-10-30 |
| Phase | Phase 1 |
What NCT04464759 shows while recruiting
NCT04464759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04464759 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04464759 about?
NCT04464759 is a clinical study titled "A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma". This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.
What is the current status of trial NCT04464759?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2020-10-21. Estimated completion is 2025-10-30.
What conditions does trial NCT04464759 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT04464759?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04464759?
This trial is sponsored by Ravi Amaravadi, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04464759 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04464759's enrollment target sits among peer trials
94 116th of 266 higher than 150 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT05055609 · 94 participants · Phase 1
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI